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Experiência de 6 Anos de Cirurgia Micrográfica de 
Mohs num Hospital Português       
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Dermatology Department, Egas Moniz Hospital, Lisbon, Portugal 
RESUMO – Introdução: A cirurgia micrográfica de Mohs é um método cirúrgico de tratamento dos tumores cutâneos que consis-
te no controlo histológico das margens do tumor usando cortes horizontais em camadas finas congeladas a fresco. Esta técnica 
é uma indicação preferencial para tumores cutâneos da face (carcinoma basocelular e espinocelular, entre outros) associados a 
maior risco de recidiva, tumores recidivados, com margens clínicas indefinidas, quando existe envolvimento perivascular e pe-
rineural ou com subtipos histológicos agressivos. Métodos: Os autores realizaram um estudo retrospetivo de um período de 6 
anos (de julho 2012 até junho 2018) num hospital Português – Hospital de Egas Moniz, para definir as características dos doentes 
submetidos a cirurgia micrográfica de Mohs e avaliar as vantagens desta técnica. Foram analisados os fatores: idade, género, 
proveniência, diagnóstico, localização do tumor, número de estádios da cirurgia micrográfica de Mohs, tipo de reconstrução do 
defeito cirúrgico, seguimento e recidiva. Resultados: Foram operados 835 tumores no total, 459 em doentes do sexo masculino 
e 376 em doentes do sexo feminino. A média de idades foi de 71 anos (intervalo entre 23- 95 anos). A maioria dos tumores sub-
metidos a cirurgia micrográfica de Mohs foram carcinomas basocelulares (87%) localizados na pirâmide nasal (43%). Em 44% 
dos casos, houve necessidade de realizar mais de um estadio micrográfico. Metade dos encerramentos do defeito cirúrgico foram 
realizados por enxerto ou retalho cutâneo. Em doentes com seguimento igual ou superior a 3 anos, a taxa de recidiva foi de 4,9%. 
Discussão: O diagnóstico mais frequente foi o de carcinoma basocelular, o que reflete a importância da cirurgia micrográfica 
de Mohs, neste tipo de neoplasia cutânea, quer em lesões primárias como persistente/recorrentes. Salientamos que compara-
tivamente a outras revisões europeias de cirurgia de Mohs, a taxa de recidiva dos tumores se encontra dentro dos parâmetros 
normais. Este dado é particularmente relevante, se considerarmos que o nosso serviço recebe doentes enviados de hospitais e 
dermatologistas de todo o país, especialmente selecionados quanto à agressividade tumoral ou já recidivados. O intervalo médio 
de recorrência para MMS foi de 27,9 meses, o que demonstra a necessidade de um seguimento a longo prazo destes doentes. 
Conclusão: A cirurgia micrográfica de Mohs permite menores taxas de recidiva comparativamente á excisão cirúrgica simples 
pelo que a sua prática deve ser encorajada em tumores devidamente selecionados. O controlo cirúrgico das margens em vez 
das “margens cegas” é uma mais-valia tanto na poupança de tecido são como na garantia da excisão completa do tumor num 
mesmo tempo cirúrgico. 
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6 Years’ Experience of Mohs Micrographic Surgery 
in a Portuguese Hospital    
ABSTRACT – Introduction: Mohs micrographic surgery (MMS) is a surgical method of treating skin tumors that consists of histolo-
gical control of the tumor margins using horizontal slices in thin, freshly frozen layers. This technique is a preferred indication for 
cutaneous facial tumors (basal and squamous cell carcinoma, among others) associated with higher risk of recurrence, recurrent 
tumors, tumors with undefined clinical margins, when there is perivascular and perineural involvement or with aggressive histolo-
gical subtypes. Methods: The authors carried out a retrospective study of a 6-year period (from July 2012 until June 2018) at a 
Portuguese hospital – Egas Moniz hospital, to define the characteristics of patients undergoing Mohs micrographic surgery and 
to evaluate the advantages of this technique. The following factors were analyzed: age, gender, provenience, diagnosis, tumor 
location, number of stages of MMS, type of reconstruction of the surgical defect, follow-up and recurrences. Results: A total of 
835 tumors were excised, 459 in male patients and 376 in female patients. The mean age at surgery was 71 years old (range 23- 
95 years). Most of the lesions submitted to MMS were basal cell carcinomas (87%) and the most common location was the nasal 
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INTRODUCTION
Skin cancer is the most common malignancy, with basal 
cell carcinoma (BCC) being the most common type, followed 
by squamous cell carcinoma (SCC). In the last decades, there 
has been a rise in the incidence of nonmelanoma skin can-
cers.1 
Mohs micrographic surgery (MMS) is a surgical techni-
que that allows evaluation of the entire peripheral and deep 
margins of excised skin malignancies, leading to higher cure 
rates, compared to conventional excision.2
MMS also preserves the maximum normal adjacent tissue 
possible, resulting in smaller resection defects, and this can 
be especially important in aesthetic and functional areas, as 
in the face.1,2 
MMS represents an option for different types of skin ma-
lignancies, ranging from basal cell carcinoma, squamous 
cell carcinoma, atypical fibroxanthoma, dermatofibrosarco-
ma protuberans, Merkel cell carcinoma, microcystic adnexal 
carcinoma, sebaceous carcinoma, eccrine porocarcinoma, 
leiomyosarcoma, extramammary Paget’s disease, aggressi-
ve digital papillary adenocarcinoma and even melanoma.2 
It can be used for the treatment of primary or recurrent/per-
sistent tumors.3
This technique involves a series of steps that ensue in 
tumor excision, while allowing the repair of the surgical de-
fect on the same day.2 Despite being regarded as a laborious 
technique, different studies have shown a superior benefit/
cost as compared to conventional excisions or radiotherapy.4
Candidates for this procedure include: large lesions 
(measuring >2 cm), aggressive histological subtypes of BCC 
and SCC, ill-defined margins, incompletely excised or re-
current lesions and high-risk anatomical locations (such as 
central face, eyebrows, eyelids, periorbital area, nose, lips, 
chin, mandible, preauricular and retroauricular areas, tem-
ple, ears, genitals, areola, nipples, hands and feet.5-7
There is a paucity of Portuguese centers performing MMS 
surgery, making our institution an unofficial referral center 
for patients from all over the country, with more aggressive, 
recurrent or high-risk tumors. 
We present a retrospective study of all patients submitted 
to MMS surgery during a period of 6 years in a Portuguese 
Dermatology Department.
MATERIAL AND METHODS
Patients
The study was conducted at the Department of Dermato-
logy at Egas Moniz hospital in Lisbon, Portugal. We retros-
pectively analyzed all patients who have undergone MMS 
between July 2012 and June 2018.
The indications for MMS were tumor site (especially cen-
tral face), tumor size (especially >2 cm), poor clinical defi-
nition of tumor margins and recurrent lesions.
Most tumors were selected clinically, without a confirma-
tory cutaneous biopsy.
Surgical Procedure
The surgical procedure started with outlining the tumor 
margins with ink, before administrating local anesthesia. After 
this, the tumor was removed or “debulked” with a scalpel or 
curette. Following this, tumors were excised at an angle of 45º 
and the specimen was divided into sizes appropriate for fro-
zen sectioning and marked with colored dyes to enable ma-
pping of the tumor. The tissue stains used were hematoxylin 
and eosin (H&E) and toluidine blue (if basal cell carcinoma 
was suspected). After that, the surgeon evaluated the margins 
microscopically. If the margins proved to be positive, another 
MMS stage was performed. If the margins were negative, the 
surgeon would proceed with the repair of the surgical defect. 
Reconstruction of the surgical defect was performed on 
the same day of tumor excision, except for the cases left for 
secondary intention or referred to other surgical specialties 
(like Plastic surgery and Otorhinolaryngology). Every surgery 
was performed or supervised by a Mohs surgeon certified by 
the European Society for Micrographic Surgery.
Data Analysis
We evaluated factors such as: age, gender, provenience, 
diagnosis, tumor location, number of stages of MMS, type 
of reconstruction of the surgical defect, follow-up and recur-
rences.
In terms of tumor recurrence or persistence after surgery, 
we defined persistent tumors as tumors that were present 
despite treatment with topical chemotherapeutics, cryothe-
rapy, electrodesiccation and curettage or simple excision in 
the previous 6 months.  Tumors were defined as recurrent 
pyramid (43%). In 44% of the cases, it was necessary to perform more than one micrographic stage. Half of the surgical defect 
closures were performed by graft or skin flap. Considering patients with a follow up equal or superior to 3 years, the recurrence 
rate was 4.9%. Discussion: The most frequent diagnosis was basal cell carcinoma, reflecting the importance of MMS in this type 
of skin malignancy, in both primary and persistent/recurrent lesions. Compared to other European surgery reviews, our recurrence 
rate is within normal range. This fact is particularly relevant, if we consider that our institution receives patients sent from hospitals 
and dermatologists from all over the country, specially selected for tumor aggressiveness or previous relapse. More than half of 
these patients were referred from other centers and consisted of persistent/recurrent basal cell carcinomas. The follow-up at recur-
rence for MMS was 27.9 months, supporting that a long follow-up of these patients is necessary. Conclusion: MMS allows lower 
rates of recurrence compared to simple surgical excision, so its practice should be encouraged in selected tumors. The surgical 
control of the margins instead of the “blind margins” is an advantage in saving healthy tissue and allows the complete excision 
of the tumor in the same surgical time.  
KEYWORDS – Mohs Surgery; Portugal; Skin Neoplasms / surgery.
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if a previous treatment had been performed more than 6 
months before.
RESULTS
In total, during these 6 years, MMS was carried out on 
835 patients, 459 (55%) males and 376 (45%) females with 
a median age at surgery of 71 years (range 23–95 years). 
Most patients (59%) were followed at the department of Der-
matology of Egas Moniz hospital. The rest of the patients 
was referred from different institutions, either private or pu-
blic hospitals (Fig. 1).
The most frequent diagnosis after histopathological eva-
luation was basal cell carcinoma accounting for 79% of the 
total of lesions (n=728 tumors), followed by squamous cell 
carcinoma (6.3%, n=53 tumors). The other excised lesions 
were actinic keratosis (1.8%, n=15), dermatofibrossarcoma 
protuberans (1.4%, n=12), atypical fibroxanthoma (0.2%, 
n=2), Merkel carcinoma (0.1%, n=1), verrucous carcino-
ma (0.1%, n=1), malignant melanoma (0.1%, n=1), poro-
carcinoma (0.1%, n=1) and keratoacanthoma (0.1%, n=1) 
(Table 1). In 2.4% of cases no lesion was found, despite the 
fact that some of these lesions had a prior biopsy confirming 
cutaneous malignancy. 
The two most frequent diagnosis were basal cell carcino-
ma and squamous cell carcinoma, mainly primary (69.5% 
and 69.8%, corresponding respectively to 506 and 37 tu-
mors). The remaining cases were recurrences (20.1% and 
17%, corresponding respectively to 146 and 9 tumors) or 
persistence (8.2% and 1.9%, corresponding respectively to 
60 and 6 tumors) after either conventional excision or MMS.
The most common tumor location was the nose (43%, 
n=113). Lesions located on the scalp, trunk, abdomen, 
limbs and lumbar areas were excised by MMS given the 
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Table 1 - Histopathological diagnosis from tumors 
excised by MMS.
Excised lesions Number of surgeries
Basal cell carcinoma 728
Squamous cell carcinoma 53
Absence of tumor* 20
Actinic keratosis 15
Dermatofibrossarcoma 
protuberans
12
Atypical fibroxanthoma 2
Merkel carcinoma 1
Verrucous carcinoma 1
Malignant melanoma 1
Porocarcinoma 1
Keratoacanthoma 1
Total 835
* Some cases with a biopsy proven basal cell carcinoma, had histopathology 
without malignancy after MMS. 
Figure 1 - Patient referral. Most patients were followed at dermatology consultation of Egas Moniz hospital after referral from primary care. Patients 
that came directly from Egas Moniz Hospital, were referred from other surgical specialties, such as, Plastic surgery. HSAC – Hospital Santo António dos 
Capuchos. 
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extensive dimensions or poorly defined margins. A detailed 
location is present on Table 2.
The number of stages of MMS required to excise the en-
tire lesion ranged from one to seven. Most frequently, only 
one stage was necessary (56%, n=468) for removing the 
complete lesion. Just one case needed seven stages and it 
ended up being negative, confirming the total removal of 
the malignancy (Fig. 2).
The resection was completed in 98.2% of the lesions 
(n=820). In 15 cases, it was not possible to remove the 
whole lesion, because of an extensive surgical defect, deep 
invasion of the tumor or patient refusal to proceed with the 
surgery.
For repairing the surgical defect, linear closure was the 
principal option (41%, n=342), but in about half the cases, 
it was necessary to perform a skin graft or skin flap, re-
flecting the complexity of the surgical defects created after 
tumor excision (Fig. 3). Skin flaps that were performed were: 
transposition flap (13.4%, N=112), advancement flap 
(8.7%, n=73), rotation flap (4.9%, n=41), A-T flap (2.8%, 
n=23) and island flap – V-Y myocutaneous (2.3%, n=19). 
The remaining cases consisted of closure by other surgical 
specialties (4.8%, 37 were performed by Plastic Surgery and 
one case by Otorhinolaryngology) or closure by secondary 
intention (5%, n=43).
The maximum follow-up registered was 77 months. Two 
hundred and thirty three patients (28%) had a follow up in-
ferior to 3 months, 381 (46%) had a follow-up between 3 
months and 3 years and 221 (26%) patients were followed 
for more than 3 years. Considering patients with a follow-up 
equal or superior to 3 years, the recurrence rate was 4.9% 
Table 2 - Location of the excised tumors by 
anatomical area.
Tumor location Number of tumors
Nose – dorsum 113
Nose – wings 107
Nose – nasolacrimal sulcus 58
Nose - tip 56
Zygomatic region 51
Scalp 48
Forehead 43
Temporal region 38
Retroauricular region 29
Eye – inferior eyelid 26
Eye – inner cantus 25
Preauricular region 24
Ear - lobule 23
Ear – helix 21
Nasogenian sulcus 20
Supraciliar region 20
Mental region 16
Glabella 15
Cheek 14
Trunk 9
Eye – outer cantus 6
Eye – superior eyelid 6
Ear – concha 6
Scapular region 5
Abdomen 4
Limbs 3
Nose - columella 3
Ear - tragus 2
Neck 2
Inferior lip 2
Lumbar region 1
Total 835
Figure 2 - Number of MMS stages performed in each patient. 
Figure 3 - Type of repair of the surgical defect after MMS. 
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(11 patients) and they were all basal cell carcinomas. Their 
histological subtypes were infiltrative (5 patients), morphea-
form (3 patients), ulcerative (2 patients) and micronodular 
(1 patient). Of these, 54,5% were referred from other hospi-
tals, had more than 2 stages of MMS performed and 54.5% 
needed closure of the surgical defect by a flat or a graft. 
54.5% were female patients and the median follow-up at 
recurrence was 27.9 months (Table 3).
DISCUSSION
Our data are in accordance with other studies, concer-
ning the median patient age at surgery.1,6 A considerable 
amount (41%) of patients were referred from other Portu-
guese centers, although our department is not an official 
reference center for MMS.
The most frequent diagnosis was basal cell carcinoma, 
reflecting the higher prevalence of this skin malignancy, but 
also the importance of MMS, in the treatment of both prima-
ry and persistent/recurrent lesions, as reported in different 
series where MMS offers 5-year cure rates of 99%, for pri-
mary BCC and 94.4% for recurrent BCC, which are superior 
if we compare with conventional excision (90 % for primary 
BCC and 80% for recurrent BCC).2
As stated, MMS has clear advantages when dealing with 
lesions where “saving skin” is fundamental.5,7 Therefore, le-
sions on the facial area, mainly the nasal pyramid, were 
the most frequently excised. This offers greater aesthetic and 
functional results with smaller surgical defects, when com-
paring with conventional excision.1,2
As for the number of stages of MMS required to excise 
the entire lesions, in 44% more than 2 stages were neces-
sary, reflecting the higher surgical difficulty of the tumors.
Only considering patients with a follow-up superior to 
three years, a recurrence rate of 4.9% was recorded, which 
falls within the interval reported by European databases 
(1.7-6.7%).8,9 Reasons for explaining recurrence after MMS 
are failure to excise more tissue when a dense inflamma-
tory infiltrate is present, presence of residual tumor at the 
margins, missing epidermis or dermis, multifocal tumor and 
wrong inking of the lesion.10 In our case, recurrence results 
may also be due to a higher complexity of the tumors (lar-
ger, more infiltrative and more aggressive) as more than 
half of these patients with recurrent disease were complex 
cases, referred from other centers, mostly persistent/recur-
rent basal cell carcinomas that needed closure by skin flap 
or skin graft. 
We evaluated only patients with a follow-up > 3 years to 
avoid underestimation of recurrence in case of short follow-
-up, as most recurrences are reported after 5 years of treat-
ment.11 This is in agreement with our late recurrence after 
MMS (27.9 months), supporting that a long follow-up of 
these patients is necessary. 
Limitations
As a retrospective study there are several limitations in 
our study. 
Some patients had a short follow-up as for those referred 
from other hospitals they were referred back to their original 
hospital after the evaluation at 2-3 months with consequent 
loss of follow-up, and in other cases several patients missed 
their appointments. 
Unfortunately, not all patients had a cutaneous skin 
biopsy before MMS, which led to unnecessary surgery in 
cases of actinic keratosis (1.8%). Despite this, the overall 
diagnosis accuracy was high, given that all the other excised 
tumors had an indication to be removed.
Also, some indications to perform MMS, like presence 
of neurological symptoms and state of immunosuppression 
were not represented in our review, as we only considered 
tumor size or anatomical area of high-risk. 
Table 3 - Characteristics of the recurrences after MMS.   
Age Gender* Referral Diagnosis MMS stages Reconstruction Follow-up at recurrenceª
74 F Primary care Primary BCC 1 Linear closure 20
69 F Cascais hospital Persistent BCC 1 A-T flap 22
75 M Primary care Recurrent BCC 3 Graft 34
34 M Egas Moniz hospital Recurrent BCC 1 Graft 32
59 F Egas Moniz hospital Primary BCC 1 Graft 39
69 M Private institution Primary BCC 2 Linear closure 43
85 M Cascais hospital Recurrent BCC 3 Graft 12
62 M Private institution Recurrent BCC 7 Graft 20
68 F Private institution Recurrent BCC 2 Graft 15
79 F Primary care Primary BCC 1 Linear closure 44
75 F Primary care Primary BCC 2 Secondary intention 26
* F refers to female and M to Male. ª Follow-up is expressed in months after the initial surgery
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CONCLUSION
Mohs micrographic surgery allows lower rates of recur-
rence compared to simple surgical excision, so its practi-
ce should be encouraged in selected tumors. The surgical 
control of the margins instead of the “blind margins” is an 
advantage in saving healthy tissue, as it allows the comple-
te excision of the tumor in the great majority of the cases, 
resulting in lower recurrences and a higher patient satisfac-
tion.
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